EXECUTIVE SUMMARY

• Smith+Nephew Launches FLOW FLEXTEND™ COBLATION™ Wand for Hip Arthroscopy: Smith+Nephew announced the commercial release of the FLOW FLEXTEND™ COBLATION™ Wand, featuring articulating radiofrequency plasma technology designed to improve anatomical access and tissue resection efficiency in complex hip preservation procedures.
• Five-Year TLIF Cohort Study Highlights Crucial Role of L4-S1 Distal Lordosis: Clinical research published in Orthopedics This Week reveals that restoring at least 4 degrees of additional distal lordosis across L4-S1 significantly reduces five-year adjacent segment disease (ASD) and revision surgery rates.
• Meduloc Advances Nitinol Intramedullary Fixation with $4M Series B Financing: Meduloc closed a $4.0 million Series B round led by GenHenn Capital to fund the controlled alpha launch of its FDA-cleared flexible shape-memory nitinol implant platform for long-bone fracture osteosynthesis.

DAILY ANNOUNCEMENTS BY CATEGORY

Sports Medicine & Arthroscopy

Smith+Nephew — Commercial Launch of FLOW FLEXTEND™ COBLATION™ Wand for Hip Arthroscopy

• Summary: Smith+Nephew announced the commercial availability of the FLOW FLEXTEND™ COBLATION™ Wand, expanding its sports medicine joint preservation portfolio. Engineered specifically for the tight constraints of the hip joint, the articulating device enables versatile multi-angle plasma resection and precise ablation of labral tissue, acetabular rim pathology, and capsular structures without requiring excessive joint distraction.
• Key Details:
• Device/System Name: FLOW FLEXTEND™ COBLATION™ Wand
• Status: Commercial Product Launch / FDA 510(k) Cleared
• Clinical Significance: Improves access to difficult-to-reach anterior and posterior hip compartments while reducing collateral thermal damage and operating time during arthroscopic FAI and labral management.
• Original Source: Smith+Nephew Release — Orthopedics This Week

Spine & Orthobiologics

Clinical Cohort Study — Restoring 4 Degrees of Distal Lordosis (L4-S1) Prevents 5-Year Adjacent Segment Disease

• Summary: A five-year multicenter clinical cohort study published in Orthopedics This Week examined the biomechanical and radiographic determinants of long-term success following transforaminal lumbar interbody fusion (TLIF). The data demonstrated that achieving at least 4 degrees of additional distal lordosis at the L4-S1 segment correlated with a statistically significant decrease in adjacent segment degeneration and subsequent revision surgeries at five years, highlighting the priority of segmental lordosis restoration over global lumbar curvature alone.
• Key Details:
• Device/System Name: Segmental Distal Lordosis (L4-S1) Alignment Protocols
• Status: Multi-Center Clinical Study Publication
• Clinical Significance: Identifies an actionable intraoperative sagittal target for surgeons to mitigate adjacent segment breakdown and extend long-term fusion construct survival.
• Original Source: Clinical Study Review — Orthopedics This Week

Spine Surgery PROM Validation — LSQoL Validated as Superior Metric for Lumbar Degenerative Surgery

• Summary: A newly published validation study evaluated the Lumbar Surgery Quality of Life (LSQoL) patient-reported outcome measure in patients undergoing decompression and fusion for degenerative lumbar spine conditions. The multidimensional scoring tool exhibited superior responsiveness to functional recovery and substantially lower floor and ceiling effects compared to legacy Oswestry Disability Index (ODI) and SF-12 instruments.
• Key Details:
• Device/System Name: Lumbar Surgery Quality of Life (LSQoL) PRO Metric
• Status: Clinical Outcomes Validation Study
• Clinical Significance: Enhances clinical trial sensitivity and routine registry tracking for minimally invasive and open lumbar spine interventions.
• Original Source: LSQoL Validation Study — Orthopedics This Week

Trauma, Extremities & Materials Science

Meduloc — Closes $4M Series B to Fund Alpha Launch of Flexible Nitinol Intramedullary Platform

• Summary: Meduloc LLC completed a $4.0 million Series B financing round led by GenHenn Capital with participation from regional funds and former Major League Baseball player Andre Ethier. The capital will support the controlled clinical alpha launch of Meduloc's FDA-cleared, single-use intramedullary fixation system. Manufactured from superelastic nickel-titanium (nitinol) alloy, the implant adapts to intramedullary geometry to provide continuous dynamic compression across fracture planes.
• Key Details:
• Device/System Name: Meduloc Nitinol Intramedullary Fixation System
• Status: Series B Financing ($4.0M) / Controlled Alpha Launch
• Clinical Significance: Delivers continuous dynamic compression across fracture interfaces in osteopenic and compromised bone stock, minimizing hardware failure and non-union rates.
• Original Source: Meduloc Financing Announcement — Orthopedics This Week

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)